loading...| Preferred Name | Erenumab | |
| Synonyms |
AMG 334 AMG-334 AMG334 Aimovig ERENUMAB Erenumab |
|
| Definitions |
A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C169958 |
|
| CAS_Registry |
1582205-90-0 |
|
| code |
C169958 |
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 |
|
| Contributing_Source |
CTRP FDA |
|
| DEFINITION |
A human immunoglobulin G2 (IgG2) monoclonal antibody targeting calcitonin gene-related peptide receptor (CGRPR), that can be used in the preventive treatment of migraine. Upon subcutaneous administration, erenumab specifically targets, binds to and blocks the activity of CGRPR. This may relief CGRPR-triggered migraine. |
|
| Display_Name |
Erenumab |
|
| FDA_UNII_Code |
I5I8VB78VT |
|
| FULL_SYN |
AMG 334 AMG-334 AMG334 Aimovig ERENUMAB Erenumab |
|
| label |
Erenumab |
|
| NCI_Drug_Dictionary_ID |
814216 |
|
| NCI_META_CUI |
CL1382459 |
|
| Preferred_Name |
Erenumab |
|
| prefixIRI |
Thesaurus:C169958 |
|
| Semantic_Type |
Amino Acid, Peptide, or Protein Pharmacologic Substance |
|
| subClassOf |